The research team, led by Arun Kumar Trivedi of the Division of Cancer Biology at CSIR-CDRI, with Samradhi Singh and Swati Srivastava as co-first authors, approached the question with an unbiased lens. Rather than testing a predetermined molecular pathway, they first treated the aggressive triple-negative breast cancer cell line MDA-MB-231 with ormeloxifene and then ran the protein contents of those cells through two-dimensional gel electrophoresis, a classic but powerful proteomic technique that separates proteins first by their electrical charge and then by their molecular weight. Differentially regulated protein spots were subsequently identified by MALDI-TOF/TOF mass spectrometry, allowing the team to build a catalog of the molecular players whose abundance shifted in response to the drug.

What emerged from that catalog was strikingly coherent. When the researchers performed functional categorization and pathway-level integration of the differentially regulated proteins, the changes did not scatter across unrelated cellular processes. Instead, they converged on a coordinated cellular response characteristic of stress-induced cellular senescence, the programmed state of stable cell-cycle arrest that healthy tissues use to quarantine damaged or potentially malignant cells. In other words, the proteome of the treated cells was telling a consistent story: ormeloxifene was not merely poisoning the cells or slowing them down temporarily, it was reprogramming them toward a senescent identity.

To confirm that impression, the team deployed a battery of complementary assays. MTT viability tests showed that ormeloxifene inhibited the growth of both MCF7 cells, an estrogen receptor-positive breast cancer line, and the triple-negative MDA-MB-231 line, with half-maximal inhibitory concentrations ranging from 7 to 9 micromolar. Colony formation assays demonstrated that the drug sharply reduced the ability of surviving cells to establish new colonies, with a notably stronger effect in MCF7 cells. Flow cytometric cell-cycle analysis then revealed the mechanistic core of the growth arrest: in MCF7 cells, ormeloxifene induced a G0/G1 arrest by decreasing the levels of CDK4 and CDK6, the cyclin-dependent kinases that normally drive cells through the restriction point of the cell cycle, while simultaneously increasing the CDK inhibitors p21Cip1 and p27Kip1, the molecular brakes that clamp down on those kinases.

The senescence evidence itself came from two independent histochemical stains. Senescence-associated beta-galactosidase staining, the traditional workhorse marker of senescent cells, showed a time-dependent increase in staining after ormeloxifene treatment. Sudan Black B staining, a more recently validated method that detects lipofuscin, the oxidized pigment granules that accumulate specifically in senescent cells, corroborated the result. Critically, the team also observed increased expression of established senescence markers by immunoblotting, and they describe the senescence as irreversible, meaning the cells did not resume proliferation even after prolonged exposure. That irreversibility matters enormously in cancer biology, because a reversible arrest can be escaped by tumor evolution, whereas a permanent one cannot.

Perhaps the most clinically tantalizing result, however, came from a combination experiment. The researchers found that ormeloxifene enhanced the sensitivity of MCF7 cells to tamoxifen, the gold-standard endocrine therapy for estrogen receptor-positive breast cancer that has been in use since the 1970s. Tamoxifen resistance remains one of the most stubborn problems in breast oncology, and any agent that can resensitize tumors to the drug would be of immediate translational interest. The authors suggest that the combination of ormeloxifene and tamoxifen may represent a potential therapeutic strategy for tamoxifen-resistant breast tumors, a hypothesis that will now need to be tested in more sophisticated models and, eventually, in patients.

The safety profile argument for repurposing ormeloxifene is unusually strong. The drug acts as a selective estrogen receptor modulator with mild estrogenic activity in bone and anti-estrogenic activity in uterine and breast tissue, a tissue-selective profile that mirrors the pharmacology of drugs like raloxifene. It has been used as a reversible, non-hormonal, once-weekly oral contraceptive in India for decades, and a phase II study published as far back as 1989 by Misra and colleagues evaluated centchroman as a non-steroidal anti-cancer agent in advanced breast cancer. Subsequent laboratory work has shown antiproliferative effects in head and neck cancer through modulation of the PI3K/mTOR pathway, efficient inhibition of ovarian cancer growth, suppression of desmoplasia and enhancement of gemcitabine sensitivity in pancreatic cancer, and G0/G1 arrest with ERK-mediated apoptosis in chronic myeloid leukemia cells. The new study adds senescence induction to this growing mechanistic portfolio.

Senescence as an anticancer mechanism has a complicated history. On one hand, inducing senescent cells in a tumor is a validated therapeutic concept, and chemotherapy itself frequently works partly by triggering senescence. On the other hand, senescent cells are not inert: they can secrete inflammatory and growth-promoting factors, and chemotherapy-induced senescence has been described as an adaptive mechanism that can drive resistance and tumor heterogeneity. The authors of the current study are careful to frame their findings as evidence that ormeloxifene restrains tumor progression by promoting irreversible senescence, and the irreversibility claim is central to that framing, since a senescent state that cannot be exited is far less likely to feed tumor regrowth than a transient one.

Technically, the study is a textbook example of how classical proteomics can still open doors in the era of genomics. Two-dimensional gel electrophoresis combined with MALDI-TOF/TOF mass spectrometry is labor-intensive and lower throughput than modern shotgun proteomics, but it excels at revealing shifts in protein abundance and isoforms in a visually interpretable format, and it allowed the team to detect the senescence signature before committing to targeted validation. The downstream validation cascade, spanning MTT assays, clonogenic survival, flow cytometry, dual senescence staining and Western blotting of cell-cycle regulators, follows the standard logic of discovery-driven cancer pharmacology: find the phenotype first, then confirm it with orthogonal methods.

For now, the work remains at the cell-culture stage, conducted in two breast cancer cell lines representing the two major clinical subtypes, hormone receptor-positive and triple-negative. The IC50 values in the low micromolar range are within the reach of achievable plasma concentrations for many oral agents, and the drug’s decades of human use as a contraceptive mean that its pharmacokinetics, dosing and safety in healthy women are already well characterized, potentially shortening the path to clinical evaluation considerably. The authors acknowledge support from the CSIR-National Laboratories Scheme and the DBT-BioCARe program, and the study was conducted at CSIR-CDRI, the institution where centchroman was originally developed. If the senescence mechanism holds up in animal models and combination studies with tamoxifen, a fifty-year-old contraceptive pill could find itself reborn as a senescence-inducing partner drug for breast cancers that have stopped responding to endocrine therapy, a repurposing story that few in the field would have predicted even a decade ago.

Subject of Research: Senescence induction by the selective estrogen receptor modulator ormeloxifene in breast cancer cells

Article Title: Ormeloxifene, a non-steroidal selective estrogen receptor modulator induces senescence in breast cancer cells

Article References: Singh, S., Srivastava, S., Siddiqui, S., Sharma, A., & Trivedi, A. K. (2026). Ormeloxifene, a non-steroidal selective estrogen receptor modulator induces senescence in breast cancer cells. Molecular Biology Reports, 53(1), Article 1665. https://doi.org/10.1007/s11033-026-12839-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12839-y

Keywords: ormeloxifene, centchroman, breast cancer, cellular senescence, tamoxifen, CDK4, CDK6, p21Cip1, p27Kip1, drug repurposing, proteomics, selective estrogen receptor modulator